Antonioni Annibale, Raho Emanuela Maria, Manzoli Lamberto, Koch Giacomo, Flacco Maria Elena, Di Lorenzo Francesco
Doctoral Program in Translational Neurosciences and Neurotechnologies Department of Neuroscience and Rehabilitation University of Ferrara Ferrara Italy.
Department of Neuroscience and Rehabilitation University of Ferrara Ferrara Italy.
Alzheimers Dement (Amst). 2025 Jan 16;17(1):e70068. doi: 10.1002/dad2.70068. eCollection 2025 Jan-Mar.
Blood-based biomarkers seem promising for the diagnosis of Alzheimer's disease (AD).
We performed a systematic review and meta-analysis on the potential of blood phosphorylated Tau181 (p-tau181) to differentiate amyloid-positive (A+) and amyloid-negative (A-) subjects. Two meta-analyses were conducted, showing the mean p-tau values in blood and cerebrospinal fluid (CSF) in the A+ and A- group, and the second comparing the mean p-tau concentrations in blood and CSF among A+ versus A- participants, by laboratory assessment method.
Eighteen studies (2764 A+ and 5646 A- subjects) were included. The single-group meta-analysis showed mean higher blood p-tau181 values in the A+ than in the A- group. In the head-to-head meta-analysis, blood p-tau reliably differentiated A+ patients from A- participants.
Regardless of the laboratory technique, blood p-tau181 reliably differentiates A+ and A- subjects. Therefore, it might have important applications for early diagnosis and inclusion in clinical trials for AD patients.
The role of blood-based biomarkers in discriminating AD patients is still uncertain.Blood p-tau181 distinguishes among amyloid-positive and amyloid-negative subjects.Blood p-tau181 might allow early diagnosis and inclusion in clinical trials.
基于血液的生物标志物在阿尔茨海默病（AD）诊断中似乎很有前景。
我们对血液磷酸化Tau181（p-tau181）区分淀粉样蛋白阳性（A+）和淀粉样蛋白阴性（A-）受试者的潜力进行了系统评价和荟萃分析。进行了两项荟萃分析，第一项显示A+组和A-组血液和脑脊液（CSF）中的p-tau平均水平，第二项按实验室评估方法比较A+与A-参与者血液和脑脊液中的p-tau平均浓度。
纳入18项研究（2764例A+受试者和5646例A-受试者）。单组荟萃分析显示，A+组血液中p-tau181值平均高于A-组。在直接比较的荟萃分析中，血液p-tau能可靠地区分A+患者和A-参与者。
无论实验室技术如何，血液p-tau181都能可靠地区分A+和A-受试者。因此，它在AD患者的早期诊断及纳入临床试验方面可能具有重要应用价值。
基于血液的生物标志物在鉴别AD患者中的作用仍不确定。血液p-tau181可区分淀粉样蛋白阳性和阴性受试者。血液p-tau181可能有助于早期诊断及纳入临床试验。
